RxDoctor Payments Data

Ngan Nguyen, DPM

Podiatrist · Scottsdale, AZNPI 1376994269

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Kerecis Limited at 25.5% of the total. Reporting peaked in 2024 at $1,050 and has fallen 59.7% since, to $424 in 2025.

$2,693in general payments, 2019–2025

Across 53 payments — averaging $50.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$687
  • Smith+Nephew$516
  • Organogenesis Inc.$465
  • Mimedx Group, Inc.$347
  • Stryker$267
  • Integra Lifesciences Corporation$185
  • plus $226 from 6 others

What the payments were for

  • Food & beverage$2,63298%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,693 in reported general payments places this provider in the 75th percentile of 151 podiatrist providers in Arizona.

See all podiatrist providers in Arizona

Medicare billing

Part B allowed, 2024
$45,150
Medicare patients
253
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ammonium Lactate37$851
Ciclopirox18$619
Doxycycline Monohydrate12$239
Terbinafine Hcl28$197
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$171
Methylprednisolone11$58
Meloxicam27$36

Paid to pharmacies, not to this prescriber.

Other podiatrist in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →